Search

Your search keyword '"Hoeh, Benedikt"' showing total 396 results
Start Over Author "Hoeh, Benedikt"
396 results on '"Hoeh, Benedikt"'

5. In-Hospital Venous Thromboembolism and Pulmonary Embolism After Major Urologic Cancer Surgery

Author

Cano Garcia, Cristina, Tappero, Stefano, Piccinelli, Mattia Luca, Barletta, Francesco, Incesu, Reha-Baris, Morra, Simone, Scheipner, Lukas, Baudo, Andrea, Tian, Zhe, Hoeh, Benedikt, Chierigo, Francesco, Sorce, Gabriele, Saad, Fred, Shariat, Shahrokh F., Carmignani, Luca, Ahyai, Sascha, Longo, Nicola, Tilki, Derya, Briganti, Alberto, De Cobell, Ottavio, Dell’Oglio, Paolo, Mandel, Philipp, Terrone, Carlo, Chun, Felix K. H., and Karakiewicz, Pierre I.

Published
2023
Full Text
View/download PDF

7. First-Line Immune Combination Therapies for Nonclear Cell Versus Clear Cell Metastatic Renal Cell Carcinoma: Real-World Multicenter Data From Germany

Author

Cano Garcia, Cristina, Hoeh, Benedikt, Mandal, Subhajit, Banek, Severine, Klümper, Niklas, Schmucker, Philipp, Hahn, Oliver, Mattigk, Angelika, Ellinger, Jörg, Cox, Alexander, Becker, Philippe, Zeuschner, Philip, Zengerling, Friedemann, Erdmann, Kati, Buerk, Bjoern Thorben, Kalogirou, Charis, and Flegar, Luka

Published
2024
Full Text
View/download PDF

8. Feasibility of Next-generation Sequencing of Liquid Biopsy (Circulating Tumor DNA) Samples and Tumor Tissue from Patients with Metastatic Prostate Cancer in a Real-world Clinical Setting in Germany

Author

Mandel, Philipp, Hoeh, Benedikt, Humke, Clara, Doering, Claudia, Wenzel, Mike, Cano Garcia, Cristina, Fuhr, Nina, Koll, Florestan, Fassl, Anne, Tilki, Derya, Steuber, Thomas, Faull, Iris, Jeroch, Jan, Ebner, Silvana, Schmitt, Christina, Reis, Henning, Köllermann, Jens, Kokkaliaris, Konstantinos D., Demes, Melanie C., Chun, Felix K.H., and Wild, Peter J.

Published
2024
Full Text
View/download PDF

9. Differences in Survival of Clear Cell Metastatic Renal Cell Carcinoma According to Partial vs. Radical Cytoreductive Nephrectomy

Author

Cano Garcia, Cristina, Flammia, Rocco S., Piccinelli, Mattia, Panunzio, Andrea, Tappero, Stefano, Barletta, Francesco, Incesu, Reha-Baris, Law, Kyle W., Morra, Simone, Tian, Zhe, Saad, Fred, Kapoor, Anil, Shariat, Shahrokh F., Longo, Nicola, Tilki, Derya, Briganti, Alberto, Terrone, Carlo, Antonelli, Alessandro, De Cobelli, Ottavio, Hoeh, Benedikt, Kluth, Luis A., Chun, Felix K.H., and Karakiewicz, Pierre I.

Published
2024
Full Text
View/download PDF

13. ASO Visual Abstract: In-Hospital Venous Thromboembolism and Pulmonary Embolism After Major Urological Cancer Surgery

Author

Cano Garcia, Cristina, Tappero, Stefano, Piccinelli, Mattia Luca, Barletta, Francesco, Incesu, Reha-Baris, Morra, Simone, Scheipner, Lukas, Baudo, Andrea, Tian, Zhe, Hoeh, Benedikt, Chierigo, Francesco, Sorce, Gabriele, Saad, Fred, Shariat, Shahrokh F., Carmignani, Luca, Ahyai, Sascha, Longo, Nicola, Tilki, Derya, Briganti, Alberto, De Cobell, Ottavio, Dell’Oglio, Paolo, Mandel, Philipp, Terrone, Carlo, Chun, Felix K. H., and Karakiewicz, Pierre I.

Published
2023
Full Text
View/download PDF

19. Cancer-specific Mortality in T1a Renal Cell Carcinoma Treated with Local Tumor Destruction Versus Partial Nephrectomy

Author

Sorce, Gabriele, Hoeh, Benedikt, Hohenhorst, Lukas, Panunzio, Andrea, Tappero, Stefano, Tian, Zhe, Kokorovic, Andrea, Larcher, Alessandro, Capitanio, Umberto, Tilki, Derya, Terrone, Carlo, Chun, Felix K.H., Antonelli, Alessandro, Saad, Fred, Shariat, Shahrokh F., Montorsi, Francesco, Briganti, Alberto, and Karakiewicz, Pierre I.

Published
2023
Full Text
View/download PDF

23. Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity

Author

Chierigo, Francesco, Borghesi, Marco, Würnschimmel, Christoph, Flammia, Rocco Simone, Horlemann, Benedikt, Sorce, Gabriele, Hoeh, Benedikt, Tian, Zhe, Saad, Fred, Graefen, Markus, Gallucci, Michele, Briganti, Alberto, Montorsi, Francesco, Chun, Felix K. H., Shariat, Shahrokh F., Mantica, Guglielmo, Suardi, Nazareno, Terrone, Carlo, and Karakiewicz, Pierre I.

Published
2022
Full Text
View/download PDF

24. Effect of Inferior Vena Cava Tumor Thrombus on Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Cytoreductive Nephrectomy

Author

Hoeh, Benedikt, Flammia, Rocco Simone, Hohenhorst, Lukas, Sorce, Gabriele, Panunzio, Andrea, Tappero, Stefano, Tian, Zhe, Saad, Fred, Gallucci, Michele, Briganti, Alberto, Terrone, Carlo, Shariat, Shahrokh F., Graefen, Markus, Tilki, Derya, Antonelli, Alessandro, Kosiba, Marina, Mandel, Philipp, Kluth, Luis A., Becker, Andreas, Chun, Felix K.H., and Karakiewicz, Pierre I.

Published
2022
Full Text
View/download PDF

25. Contemporary Pathological Stage Distribution After Radical Prostatectomy in North American High-Risk Prostate Cancer Patients

Author

Chierigo, Francesco, Borghesi, Marco, Würnschimmel, Christoph, Flammia, Rocco Simone, Sorce, Gabriele, Hoeh, Benedikt, Hohenhorst, Lukas, Tian, Zhe, Saad, Fred, Tilki, Derya, Gallucci, Michele, Briganti, Alberto, Montorsi, Francesco, Chun, Felix K.H., Shariat, Shahrokh F., Mantica, Guglielmo, Suardi, Nazareno, Terrone, Carlo, and Karakiewicz, Pierre I.

Published
2022
Full Text
View/download PDF

26. Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patients

Author

Sorce, Gabriele, Flammia, Rocco Simone, Hoeh, Benedikt, Chierigo, Francesco, Horlemann, Benedikt, Würnschimmel, Christoph, Tian, Zhe, Graefen, Markus, Terrone, Carlo, Gallucci, Michele, Chun, Felix K. H., Saad, Fred, Shariat, Shahrokh F., Montorsi, Francesco, Briganti, Alberto, and Karakiewicz, Pierre I.

Published
2022
Full Text
View/download PDF

27. Metastatic stage vs complications at radical nephrectomy with inferior vena cava thrombectomy

Author

Hoeh, Benedikt, Flammia, Rocco Simone, Hohenhorst, Lukas, Sorce, Gabriele, Panunzio, Andrea, Chierigo, Francesco, Nimer, Nancy, Tian, Zhe, Saad, Fred, Gallucci, Michele, Briganti, Alberto, Shariat, Shahrokh F., Graefen, Markus, Tilki, Derya, Antonelli, Alessandro, Terrone, Carlo, Kluth, Luis A., Becker, Andreas, Chun, Felix K.H., and Karakiewicz, Pierre I.

Published
2022
Full Text
View/download PDF

28. The Association Between Lymphovascular or Perineural Invasion in Radical Prostatectomy Specimen and Biochemical Recurrence.

Author

Siech, Carolin, Wenzel, Mike, Grosshans, Nico, Cano Garcia, Cristina, Humke, Clara, Koll, Florestan Johannes, Tian, Zhe, Karakiewicz, Pierre I., Kluth, Luis A., Chun, Felix K. H., Hoeh, Benedikt, and Mandel, Philipp

Subjects
CANCER invasiveness, CANCER relapse, RADICAL prostatectomy, PROSTATE tumors, CANCER patients, TUMOR grading, DESCRIPTIVE statistics, KAPLAN-Meier estimator, ODDS ratio, COLLECTION & preservation of biological specimens, TUMOR classification, COMPARATIVE studies, CONFIDENCE intervals, PROGRESSION-free survival, PROPORTIONAL hazards models
Abstract

Simple Summary: The prognostic value of lymphovascular or perineural invasion in prostate cancer specimens regarding oncological outcomes after radical prostatectomy is unclear. Within a contemporary study cohort of 822 prostate cancer patients, 78 (9%) exhibited lymphovascular invasion and 633 (77%) exhibited perineural invasion in RP specimens. In univariable Cox regression models, lymphovascular invasion and perineural invasion were both associated with higher rates of biochemical recurrence (BCR). However, after multivariable adjustment for standard pathologic tumor characteristics, lymphovascular or perineural invasion was not found to be an independent predictor for BCR. These phenomes may be explained by the strong association between the Gleason Grade Group and pathologic tumor stage with lymphovascular as well as perineural invasion. Objective: The aim of this study was to test for the association between lymphovascular invasion or perineural invasion in radical prostatectomy (RP) specimens and biochemical recurrence (BCR). Methods: Relying on a tertiary-care database, we identified prostate cancer patients treated with RP between January 2014 and June 2023. Of these, the majority underwent robotic-assisted RP (81%). Kaplan–Meier survival analyses and Cox regression models addressed BCR according to either lymphovascular invasion or perineural invasion in RP specimens. Additionally, the linear trend test assessed the association between the Gleason Grade Group or pathologic tumor stage and lymphovascular or perineural invasion. Results: Of 822 patients, 78 (9%) exhibited lymphovascular invasion and 633 (77%) exhibited perineural invasion in RP specimens. In survival analyses, the five-year BCR-free survival rates were 62% in patients with lymphovascular invasion vs. 70% in patients without lymphovascular invasion (p = 0.04) and 64% in patients with perineural invasion vs. 82% in patients without perineural invasion (p = 0.01). In univariable Cox regression models, lymphovascular invasion (hazard ratio 1.58, 95% confidence interval 1.01–2.47; p = 0.045) and perineural invasion (hazard ratio 1.77, 95% confidence interval 1.13–2.77; p = 0.013) were both associated with a higher BCR rate. After accounting for age at surgery, PSA value, pathologic tumor stage, Gleason Grade Group, lymph node invasion, positive surgical margin, surgical approach, and adjuvant radiation therapy, lymphovascular (p = 0.740) or perineural invasion (p = 0.341) were not significantly associated with a higher BCR since the Gleason Grade Group and pathologic tumor stage highly correlated with lymphovascular as well as perineural invasion. Conclusions: In univariable models, lymphovascular or perineural invasion is associated with BCR. After adjustment for standard pathologic tumor characteristics, lymphovascular or perineural invasion is not an independent predictor for BCR. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Assessment of Different Castration Resistance Definitions and Staging Modalities in Metastatic Castration-Resistant Prostate Cancer.

Author

Wenzel, Mike, Hoeh, Benedikt, Humke, Clara, Siech, Carolin, Cano Garcia, Cristina, Salomon, Georg, Maurer, Tobias, Graefen, Markus, Bernatz, Simon, Bucher, Andreas Michael, Kluth, Luis, Chun, Felix K. H., and Mandel, Philipp

Subjects
*CASTRATION-resistant prostate cancer, *ANTIANDROGENS, *POSITRON emission tomography computed tomography, *DESCRIPTIVE statistics, *METASTASIS, *PROSTATE-specific membrane antigen, *TUMOR classification, *PROGRESSION-free survival, *OVERALL survival, *DISEASE progression
Abstract

Simple Summary: The current real-world study suggests that important differences exist in patients progressing to mCRPC. Specifically, we found that a proportion of over 20% of patients progress without a PSA level rise, emphasizing the importance of regular staging intervals. Moreover, we found that patients with worse PSA responses are at higher risk for biochemical progression, emphasizing the need for regular PSA check-ups and kinetic measurements. However, no differences in PFS and OS outcomes between these patients were observed. Finally, staging with PSMA-PET/CT might provide better PFS and OS, relative to conventionally staged mCRPC patients. However, this observation may be substantially influenced by the detection of earlier disease progression and the possibility of treatment in patients with a lower metastatic burden, as well as more contemporary patients with better treatment options. Background/Objectives: Progression to metastatic castration-resistant prostate cancer (mCRPC) is defined either biochemically, radiographically or both. Moreover, staging for mCRPC can be performed either conventionally or with molecular imaging such as prostate-specific membrane antigen computer tomography (PSMA-PET/CT). Methods: We relied on the Frankfurt Metastatic Cancer Database of the Prostate (FRAMCAP) database to compare progression-free (PFS) and overall survival (OS) outcomes regarding the cause of castration resistance and the staging modality used. Results: Overall, 35% progressed to mCRPC biochemically vs. 23% radiographically vs. 42% biochemically + radiographically. The PSA nadir in mHSPC (1.4 vs. 0.4 vs. 0.8 ng/mL) and PSA level at mCRPC progression (15 vs. 2 vs. 21 ng/mL, both p ≤ 0.01) were significantly higher for biochemical vs. radiographic vs. both progressed patients. In PFS and OS analyses, no significant differences were observed among all three compared groups. In the comparison of the staging used for progression to mCRPC, 67% received conventional vs. 33% PSMA-PET/CT, with higher metastatic burden in mHSPC and osseous lesions in mCRPC for conventionally staged patients (both p < 0.01). In PFS (15.3 vs. 10.1 months, hazard ratio [HR]: 0.75) and OS analyses (52.6 vs. 34.3 months, HR: 0.61, both p < 0.05), PSMA-PET/CT harbored better prognosis; however, this did not hold after multivariable adjustment. Similar results were observed for further analyses in second- and third-line mCRPC or patients with a PSA level of ≥2 ng/mL. Conclusions: The cause of progression to mCRPC seems not to influence cancer-control outcomes, despite important baseline tumor characteristic differences. The PSMA-PET/CT staging modality might be associated with better PFS and OS outcomes, possibly due to its more sensitive detection of progression or new metastatic lesions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Transition from Transrectal to Transperineal MRI-Fusion Prostate Biopsy Does Not Comprise Detection Rates of Clinically Significant Prostate Cancer at a Tertiary Care Center

Author

Hoeh, Benedikt, primary, Wenzel, Mike, additional, Humke, Clara, additional, Cano Garcia, Cristina, additional, Siech, Carolin, additional, Schneider, Melissa, additional, Lange, Carsten, additional, Traumann, Miriam, additional, Köllermann, Jens, additional, Preisser, Felix, additional, Chun, Felix K. H., additional, and Mandel, Philipp, additional

Published
2024
Full Text
View/download PDF

34. MP58-02 ORGAN-CONFINED PT2 ISUP4/5 VS. NON-ORGAN CONFINED ≥PT3 ISUP2/3 PROSTATE CANCER: DIFFERENCES IN BIOCHEMICAL RECURRENCE-FREE SURVIVAL AND METASTASIS-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY

Author

Wenzel, Mike, primary, Siech, Carolin, additional, Hoeh, Benedikt, additional, Rohlsen, Eike, additional, Garcia, Cristina Cano, additional, Humke, Clara, additional, Köllermann, Jens, additional, Karakiewicz, Pierre, additional, Kluth, Luis, additional, Chun, Felix, additional, and Mandel, Philipp, additional

Published
2024
Full Text
View/download PDF

36. Effect of prostatic apex shape (Lee types) and urethral sphincter length in preoperative MRI on very early continence rates after radical prostatectomy

Author

Wenzel, Mike, Preisser, Felix, Mueller, Matthias, Theissen, Lena H., Welte, Maria N., Hoeh, Benedikt, Humke, Clara, Bernatz, Simon, Bodelle, Boris, Würnschimmel, Christoph, Tilki, Derya, Huland, Hartwig, Graefen, Markus, Roos, Frederik C., Becker, Andreas, Karakiewicz, Pierre I., Chun, Felix K. H., Kluth, Luis A., and Mandel, Philipp

Published
2021
Full Text
View/download PDF

39. Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real‐world setting.

Author

Wenzel, Mike, Hoeh, Benedikt, Wagner, Nele, Koll, Florestan, Siech, Carolin, Humke, Clara, Steuber, Thomas, Graefen, Markus, Tilki, Derya, Kluth, Luis, Traumann, Miriam, Banek, Séverine, Chun, Felix K. H., and Mandel, Philipp

Subjects
*THERAPEUTIC use of antineoplastic agents, *DOCETAXEL, *ACADEMIC medical centers, *T-test (Statistics), *KRUSKAL-Wallis Test, *LIFE expectancy, *PROSTATE tumors, *TREATMENT effectiveness, *RETROSPECTIVE studies, *DESCRIPTIVE statistics, *CHI-squared test, *MULTIVARIATE analysis, *METASTASIS, *KAPLAN-Meier estimator, *CANCER chemotherapy, *ANDROGEN receptors, *OVERALL survival, *PROPORTIONAL hazards models, *REGRESSION analysis, *OLD age
Abstract

Background: The landscape of systemic therapies for metastatic hormone‐sensitive (mHSPC) and castration resistant prostate cancer (mCRPC) extensively improved within the last decades resulting in a significantly prolonged overall survival. However, subgroup analyses of phase III trials suggest potentially different overall survival outcomes for older adults. Methods: We relied on our institutional metastatic prostate cancer database to identify mHSPC and subsequently mCRPC patients. Older adults were stratified according to age groups 70–74 versus ≥75–79 versus ≥80 years at metastatic occurrence. Subsequently, uni‐ and multivariable time to mCRPC and overall survival analyses were performed. Results: Of 494 older adults, 217 (44%) were 70–74 versus 180 (36%) 75–79 versus 97 (20%) ≥80 years old. Rates of local prostate cancer treatment differed significantly between all three groups (p < 0.01). Regarding mHSPC treatment, androgen receptor signaling inhibitors (ARSI) were administered in 30–39% of patients and docetaxel with 9% in age group 70–74 years and 6% and 3% in age groups 75–79 years and ≥80 years. Regarding mCRPC treatment, significant differences between treatment proportions were observed (p < 0.01). Most common treatment was ARSI for all three groups. Conversely, chemotherapy was more frequently administered in patients aged 70–74 (16%), relative to 4% and 3% in 75‐79 year and ≥80 year aged patients. In univariable and multivariable time to mCRPC analyses, overall survival in mHSPC and OS in mCRPC analyses, no significant differences between all three age groups were observed (all p ≥ 0.3). Conclusions: Treatment patterns differ significantly between older adults with metastatic prostate cancer. However, these differences may not result in differences of overall life expectancy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real‐world setting of metastatic prostate cancer.

Author

Wenzel, Mike, Hoeh, Benedikt, Koll, Florestan, Humke, Clara, Fassl, Anne, Reis, Henning, Wild, Peter, Steuber, Thomas, Graefen, Markus, Tilki, Derya, Traumann, Miriam, Banek, Severine, Chun, Felix K.H., and Mandel, Philipp

Subjects
*HOMOLOGOUS recombination, *METASTATIC breast cancer, *GENE targeting, *CHECKPOINT kinase 2, *CASTRATION-resistant prostate cancer, *PROSTATE cancer, *BREAST cancer, *BRCA genes
Abstract

Objective Patients and methods Results Conclusion To investigate alterations of homologous recombination repair (HRR) and especially BReast CAncer 1/2 (BRCA1/2) gene on overall survival (OS). Moreover, to explore the effect of inhibition of poly(ADP‐ribose)‐polymerase (PARPi) as systemic therapy for metastatic castration‐resistant prostate cancer (mCRPC).Of all HRR‐screened patients with metastatic prostate cancer, baseline characteristics were sampled. Kaplan–Meier estimates and multivariable Cox regression models predicted the effect of HRR/BRCA1/2 alterations on OS.Of 196 eligible patients, 61 (31%) harboured any HRR and 40 (20%) BRCA1/2 alterations. Of HRR alterations, 40 (66%) vs six (10%) vs five (8.2%) vs four (6.6%) vs two (3.3%) vs four (6.6%) were BRCA1/2 vs Ataxia‐telangiectasia mutated kinase (ATM) vs checkpoint kinase 2 (CHEK2) vs cyclin‐dependent kinase 12 (CDK12) vs Fanconi anaemia complementation Group A (FANCA) vs positive for other mutations. Of these, 30% received a PARPi. OS differed significantly between HRR‐positive vs ‐negative patients. Specifically in hormone‐sensitive prostate cancer, the median OS was 63 (HRR positive) vs 57 (BRCA1/2 positive) vs 113 months (HRR negative) (P ≤ 0.01). In mCRPC, OS was 42 (HRR positive) vs 41 (BRCA1/2 positive) vs 70 months (HRR negative) (P ≤ 0.01). HRR and BRCA1/2 alterations were associated with worse OS after multivariable adjustment. Finally, patients with mCRPC with BRCA1/2 mutation treated without PARPi harboured worse OS than patients with BRCA1/2 mutation and PARPi therapy (median OS: 33 vs 48 months, P < 0.03).Incidence of HRR alteration in a clinical real‐world setting is high when using blood‐ and tissue‐based tests. Patients with HRR/BRCA alterations have worse outcomes resulting in significant OS differences between HRR/BRCA‐positive patients with mCRPC with and without PARPi usage vs HRR/BRCA‐negative patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. The Association between Patient Characteristics and Biochemical Recurrence after Radical Prostatectomy.

Author

Siech, Carolin, Wenzel, Mike, Lange, Carsten, Cano Garcia, Cristina, Humke, Clara, Tian, Zhe, Karakiewicz, Pierre I., Traumann, Miriam, Kluth, Luis A., Chun, Felix K. H., Hoeh, Benedikt, and Mandel, Philipp

Subjects
RADICAL prostatectomy, PROSTATE cancer patients, REGRESSION analysis, BODY mass index, PROSTATE surgery, GLEASON grading system, RADIOTHERAPY
Abstract

Background: Biochemical recurrence (BCR) represents the rise of prostate-specific antigen (PSA) levels after treatment with curative radical prostatectomy (RP) or radiation for prostate cancer. The objective of the current study was to test for the association between patient characteristics, namely age, body mass index (BMI), as well as prostate volume at surgery, and BCR after RP. Material and Methods: Within a tertiary care database, patients with prostate cancer treated with RP between January 2014 and June 2023 were included. Kaplan–Meier survival analyses and Cox regression models addressed BCR after RP according to patient characteristics. Results: Of 821 patients, the median age was 66 years (interquartile range [IQR] 61–71 years), BMI was 26.2 kg/m2 (IQR 24.3–28.8 kg/m2), and prostate volume was 40 cm3 (IQR 30–55 cm3). Median follow-up was 20 months. In survival analyses, the three-year BCR-free survival rates were 81 vs. 84 vs. 81% in patients aged ≤60 vs. 61–69 vs. 70 years (p = 0.1). In patients with BMI < 25.0 vs. 25.0–29.9 vs. ≥30.0 kg/m2, the three-year BCR-free survival rates were 84 vs. 81 vs. 84% (p = 0.7). In patients with prostate volume ≤40 vs. >40 cm3, the three-year BCR-free survival rates were 85 vs. 80% (p = 0.004). In multivariable Cox regression models accounting for patient and pathologic tumor characteristics and adjuvant radiation therapy, a higher prostate volume independently predicted BCR as continuous (hazard ratio 1.012, 95% confidence interval 1.005–1.019; p < 0.001), as well as categorized the variable based on the median (hazard ratio 1.66, 95% confidence interval 1.17–2.36; p = 0.005). Conversely, neither age nor BMI were significantly associated with BCR after RP. Conclusions: The higher prostate volume independently predicted BCR after RP, but not age or BMI at surgery. Consequently, patients with an elevated prostate volume should be considered for closer postoperative follow-up. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Real-World Evidence of Tumor and Patient Characteristics and Survival with Avelumab Maintenance after Chemotherapy for Advanced and Metastatic Urothelial Carcinoma

Author

Banek, Séverine, primary, Wenzel, Mike, additional, Lauer, Benedikt, additional, Le, Quynh Chi, additional, Hoeh, Benedikt, additional, Koll, Florestan, additional, Cano Garcia, Cristina, additional, Humke, Clara, additional, Köllermann, Jens, additional, Chun, Felix K.H., additional, Kosiba, Marina, additional, and Kluth, Luis A., additional

Published
2024
Full Text
View/download PDF

44. Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis

Author

Glaser, Fabian, John, Clara, Engel, Bastian, Höh, Benedikt, Weidemann, Sören, Dieckhoff, Jan, Stein, Stephanie, Becker, Nathalie, Casar, Christian, Schuran, Fenja Amrei, Wieschendorf, Björn, Preti, Max, Jessen, Friederike, Franke, Andre, Carambia, Antonella, Lohse, Ansgar W., Ittrich, Harald, Herkel, Johannes, Heeren, Joerg, Schramm, Christoph, and Schwinge, Dorothee

Published
2019
Full Text
View/download PDF

45. The association of type and number of high-risk criteria with cancer-specific mortality in prostate cancer patients treated with radical prostatectomy.

Author

Chierigo, Francesco, Flammia, Rocco Simone, Sorce, Gabriele, Hoeh, Benedikt, Hohenhorst, Lukas, Panunzio, Andrea, Tian, Zhe, Saad, Fred, Graefen, Marcus, Gallucci, Michele, Briganti, Alberto, Montorsi, Francesco, Chun, Felix K.H., Shariat, Shahrokh F., Antonelli, Alessandro, Guano, Giovanni, Mantica, Guglielmo, Borghesi, Marco, Suardi, Nazareno, and Terrone, Carlo

Published
2024
Full Text
View/download PDF

48. Impact of consensus molecular subtypes on survival with and without adjuvant chemotherapy in muscle-invasive urothelial bladder cancer

Author

Koll, Florestan J, primary, Döring, Claudia, additional, Herwig, Leon, additional, Hoeh, Benedikt, additional, Wenzel, Mike, additional, Cano Garcia, Cristina, additional, Banek, Severine, additional, Kluth, Luis, additional, Köllermann, Jens, additional, Weigert, Andreas, additional, Chun, Felix K-H, additional, Wild, Peter, additional, and Reis, Henning, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results